Retrospective Study
Copyright ©The Author(s) 2025.
World J Virol. Jun 25, 2025; 14(2): 97421
Published online Jun 25, 2025. doi: 10.5501/wjv.v14.i2.97421
Table 2 Overall trends of outcomes in patients hospitalized for hepatitis A virus in the United States from 2011-2020, n (%)
Unmatched hepatitis A virus
VariableNo substance useActive substance useTotal
Number of hospitalizations405031543056972
Inpatient mortality396 (0.98)100 (0.65)496 (0.87)
Mean LOS, days (SE)4.22 (0.02)4.27 (0.05)4.23 (0.02)
Inflation-adjusted mean inpatient charge, United States dollar (SE)13440.49 (88.45)9280.17 (103.62)12299.86 (70)
Infective endocarditis59 (0.15)250 (1.62)309 (0.54)
Intra-abdominal abscess188 (0.46)40 (0.26)238 (0.42)
Sepsis353 (0.87)265 (1.72)618 (1.08)
Acute liver failure2666 (6.58)1177 (7.63)3893 (6.83)
AKI3820 (9.43)928 (6.01)4763 (8.36)
Respiratory failure933 (2.30)245 (1.59)1193 (2.09)
Blood transfusion670 (1.65)60 (0.39)740 (1.30)
Cellulitis806 (1.99)904 (5.86)1725 (3.03)
Venous thromboembolism117 (0.29)25 (0.16)142 (0.25)
Cardiomyopathy744 (1.84)190 (1.23)934 (1.64)
CHF2091 (5.16)314 (2.03)2405 (4.22)
Propensity score matched hepatitis A in 13079 patients
VariableNo substance useActive substance useP value
Inpatient mortality94 (0.72)100 (0.76)0.6
Mean LOS, days (SE)3.97 (0.04)4.34 (0.05)< 0.001
Inflation-adjusted mean inpatient charge, United States dollar (SE)10417.43 (129.44)9521.75 (103.53)< 0.001
Infective endocarditis20 (0.15)188 (1.44)< 0.001
Intra-abdominal abscess66 (0.50)40 (0.31)0.011
Sepsis129 (0.99)243 (1.86)< 0.001
Acute liver failure900 (6.88)992 (7.58)0.028
AKI883 (6.75)824 (6.30)0.140
Acute respiratory failure267 (2.04)224 (1.71)0.050
Need for blood transfusion166 (1.27)55 (0.42)< 0.001
Cellulitis267 (2.04)750 (5.73)< 0.001
Venous thromboembolism10 (0.08)20 (0.15)0.068
Cardiomyopathy101 (0.77)180 (1.38)< 0.001
Congestive heart failure219 (1.67)304 (2.32)< 0.001